P-121: Real-world glycemic outcomes of advanced hybrid closed-loop system (AHCL) in young children aged 2–6 years with type 1 diabetes across Latin America
L E Calliari, F Riera, C Sepulveda, M Raggio, P Paz Povedano, M Liu, M Castro, J McVeanAbstract
Introduction
The MiniMed™ 780G (MM780G) system is approved for children aged 2–6 years with type 1 diabetes (T1D) in Europe, Middle East and Africa (EMEA) following the LENNY randomized controlled trial, but its use in Latin America (LATAM) is currently off/label. Characterizing real-world outcomes of this practice is necessary to confirm that the performance reported in the LENNY study – a randomized clinical trial comparing MM780G to usual care in Europe- aligns in the real-world setting.
Objectives
To describe the device use and real-world glycemic outcomes of the MM780G system in children aged 2–6 years with T1D across four LATAM countries.
Methods
Carelink data from MM780G users aged 2–6 years from Argentina, Brazil, Chile, and Colombia (total n=423) were included. Glycemic outcomes included TIR (70–180 mg/dL), TITR (70–140 mg/dL), TAR (180-250 and >250 mg/dL), TBR (70-54 and <54 mg/dL), glucose management indicator (GMI), mean sensor glucose (SG), and coefficient of variation CV%. Insulin delivery parameters and device settings (AIT and glucose target) were also characterized.
Results
Overall mean TIR was 67.0 ± 8.6%, GMI 7.0 ± 0.3%, and TBR <54 mg/dL 0.8 ± 0.7%, with 35.7% of users achieving TIR >70% and 69.0% maintaining TBR <54 below 1%. Nighttime glycemia was consistently superior to daytime (Table 1). Automated correction boluses accounted for 30.2 ± 12.6% of all bolus deliveries. The predominant device configuration was a glucose target of 120 mg/dL (54.9%) with AIT 2–3 hours (64.7%).
Conclusions
The use of the MM780G AHCL system in children aged 2–6 years across LATAM yielded consistent and clinically significant glycemic outcomes that mirror those reported in the LENNY study.
The concordance across geographically and culturally distinct cohorts underscores the MM780G’s algorithmic robustness, supporting its potential as an effective therapy for this vulnerable age group.